Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sensicold is a fixed-dose combination oral syrup developed and marketed by Docventures Pharmaceuticals for the symptomatic relief of the common cold, influenza, and allergic rhinitis. The formulation contains three active small molecule ingredients: paracetamol (acetaminophen), phenylephrine hydrochloride, and chlorpheniramine maleate. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Phenylephrine hydrochloride acts as a sympathomimetic nasal decongestant by stimulating alpha-1 adrenergic receptors to induce vasoconstriction in the nasal mucosa. Chlorpheniramine maleate is a first-generation antihistamine that antagonizes H1 receptors to alleviate allergic symptoms such as sneezing, rhinorrhea, and watery eyes. The product is primarily marketed in India for both pediatric and adult use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sensicold.